摘要
目的:研究高血压脑出血患者行锥颅穿刺抽吸引流血肿清除术治疗的效果及对超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、神经元特异性烯醇化酶(NSE)的影响。方法:选取2016年1月-2018年1月本院收治的90例高血压脑出血患者,按照随机抽签法将其均分为试验组和对照组,各45例。对照组予以传统开颅手术治疗,试验组则采用锥颅穿刺抽吸引流血肿清除术治疗。比较两组手术指标水平,治疗前后血清hs-CRP、IL-6、NSE水平及神经功能缺损评分(NIHSS),术后并发症发生情况。结果:试验组手术时间、住院时间、住院费用均低于对照组(P<0.05);治疗后,试验组血清hs-CRP、IL-6、NSE水平及NIHSS评分均低于对照组(P<0.05);试验组术后并发症发生率为8.89%,低于对照组的28.89%(P<0.05)。结论:锥颅穿刺抽吸引流血肿清除术治疗高血压脑出血效果显著,有利于促进患者早日康复,且有效减轻患者炎症反应程度,改善患者神经功能,降低术后并发症发生风险。
Objective:To study the effects of conical craniopuncture aspiration hematoma removal in patients with hypertensive intracerebral hemorrhage and its effect on hypersensitive c-reactive protein(hs-CRP),interleukin-6(IL-6),and neuron-specific enolase(NSE).Method:A total of 90 patients with hypertensive intracerebral hemorrhage treated in our hospital from January 2016 to January 2018 were selected.According to the random lottery method,they were divided into experimental group and control group,45 cases in each group.The control group was treated with traditional craniotomy,while experimental group was treated with conical craniopuncture aspiration hematoma removal.The levels of surgical indicators,serum hs-CRP,IL-6,NSE,NIHSS before and after treatment,and complications between two groups were compared.Result:The operation time,hospitalization time and hospitalization expenses of experimental group were lower than those of control group(P<0.05).After treatment,the serum levels of hs-CRP,IL-6,NSE and NIHSS in experimental group were lower than those of control group(P<0.05).The incidence of postoperative complications in experimental group was 8.89%,which was lower than 28.89%of control group(P<0.05).Conclusion:Conical craniopuncture aspiration hematoma removal is effective in treatment of hypertensive intracerebral hemorrhage,which is conducive to the early recovery of patients,and can effectively reduce the degree of inflammation,improve the neurological function of patients,and reduce the risk of postoperative complications.
作者
赵振林
赵思蓉
刘康峰
肖华
ZHAO Zhenlin;ZHAO Sirong;LIU Kangfeng(Huadu District People’s Hospital of Guangzhou City,Guangzhou 510800,China)
出处
《中国医学创新》
CAS
2019年第16期64-68,共5页
Medical Innovation of China
基金
广州市花都区卫生局审批项目(16HDWS-046)
